Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure

NCT00180258 | Completed Phase 2

• 1 other identifier: Clinicals0002
• Study Type: interventional
• Target: 2,200
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether combined mortality and hospitalization in heart failure patients receiving optimal pharmacologic therapy can be reduced by combining optimal pharmacologic therapy and 1) biventricular pacing therapy alone or 2) biventricular pacing with defibrillation.

Conditions

Congestive Heart Failure

Keywords

Cardiac Resynchronization Therapy (CRT); Heart Failure; Defibrillator; Pacemaker

Outcome Measures

Primary Outcomes (1)

• Combination of all-cause mortality and first hospitalization (time to first event), where all-cause mortality is defined as death from all causes.

Secondary Outcomes (1)

• Total survival for both the CONTAK CD and CONTAK TR CHFDs when used in conjunction with pharmacologic therapy.

Interventions

Cardiac Resynchronization Therapy with & without defibrillator DEVICE

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Moderate or severe heart failure, defined as symptomatic heart failure for at least six months with NYHA Class III or IV symptoms at the time of enrollment, AND at least one of the following events in the previous 12 months:
• Hospitalization for heart failure management
• Outpatient visit in which intravenous (IV) inotropes or vasoactive infusion were administered continuously for at least 4 hours
• Emergency room visit of at least twelve hours duration in which IV heart failure medications were administered (including diuretics)
• QRS \> or = 120 ms and PR interval \> 150 ms from any two leads of a 12-lead ECG
• Left ventricular ejection fraction \< or = 35%
• Left ventricular end diastolic dimension \> or = 60 mm (required only if LVEF measured by echo) or \> 3.0 cm/m2 \[The cm/m2 is calculated by LVEDD (in cm) divided by BSA (body surface area)\].
• Age \> or = 18 years
• Optimal pharmacologic therapy for heart failure

You may not qualify if:

• Unable or unwilling to undergo device implant and follow-up testing
• Meet the general indications for an implantable cardioverter defibrillator
• Meet the general indications for antibradycardia pacing
• Expected to receive a heart transplant in the next six months
• Chronic, medically refractory atrial tachyarrhythmias
• Unexplained syncope
• Myocardial infarction within 60 days of randomization
• History of non-compliance with oral heart failure therapy
• Progressive or unstable angina
• Uncontrolled blood pressure: Systolic BP \> 160 mm Hg or \< 85 mm Hg or diastolic BP \> 90 mm Hg
• Patients with a hypersensitivity to a 0.7 mg nominal dose of dexamethasone acetate
• Surgically uncorrected primary valvular heart disease
• Coronary artery disease (CAD) in which surgical or percutaneous correction is recent (within 60 days of randomization)
• Women who are pregnant or not using medically acceptable birth control
• Hypertrophic obstructive cardiomyopathy

Sponsors & Collaborators

• Boston Scientific Corporation: lead

Study Sites (1)

Multiple locations in the US

Saint Paul, Minnesota, United States

Location

Related Publications (3)

• Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50. doi: 10.1056/NEJMoa032423.

  PMID: 15152059 RESULT

• Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 Jun;24(6):1080-1090. doi: 10.1002/ejhf.2524. Epub 2022 May 22.

  PMID: 35490339 DERIVED

• Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009 Feb 24;119(7):969-77. doi: 10.1161/CIRCULATIONAHA.108.793273. Epub 2009 Feb 9.

  PMID: 19204305 DERIVED

MeSH Terms

Conditions

Heart Failure

Interventions

Cardiac Resynchronization Therapy; Defibrillators

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiac Pacing, Artificial; Electric Stimulation Therapy; Therapeutics; Electrodes; Electrical Equipment and Supplies; Equipment and Supplies

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 9, 2005
• First Posted: September 16, 2005
• Study Start: January 1, 2000
• Study Completion: December 1, 2002
• Last Updated: January 25, 2007

Record last verified: 2007-01

Locations

US (1)